Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
25 mars 2021 07h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
Fate Therapeutics to Present at Upcoming Investor Conferences
08 mars 2021 07h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, March 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
24 févr. 2021 16h01 HE
|
Fate Therapeutics, Inc.
Positive Interim Data Reported from FT516 Phase 1 Study in Relapsed / Refractory BCL; Objective Responses, including Two Complete Responses, Achieved in 3 of 4 Patients in Dose Cohorts 2 and 3 ...
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
22 févr. 2021 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
19 févr. 2021 08h00 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
08 janv. 2021 16h26 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
06 janv. 2021 00h30 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
04 janv. 2021 16h01 HE
|
Fate Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Presents Patient Case Study Demonstrating Clinical Activity of FT596 in Refractory Diffuse Large B-cell Lymphoma
06 déc. 2020 10h05 HE
|
Fate Therapeutics, Inc.
Off-the-Shelf, iPSC-derived CAR NK Cell Product Candidate Drives Partial Response at First Dose Level of 30 Million Cells Deepening of Response Observed with FT596 Retreatment Duration of Response...
Fate Therapeutics Reports Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma
04 déc. 2020 16h01 HE
|
Fate Therapeutics, Inc.
3 of 4 Patients Evaluable for Efficacy in Dose Escalation Cohorts 2 and 3 Show Objective Response, with 2 Patients Achieving Complete Response No Observed Events of Any Grade of Cytokine Release...